There is evidence from the present study that the presence of the shy-drager syndrome in children with behavioral disturbances and behavioral disorder with poor social relations.
In a recent study, findings suggest that SDDS cannot be cured but the symptoms can be greatly reduced with early detection and well-tailored treatment plans in childhood.
This clinical entity may be due to a genetic defect altering neurotransmission or development of certain brain lesions. It is a potential and hitherto undescribed association of shy-drager syndrome with schizophrenia.
People with SD often suffer anxiety and loneliness, and the combination of this along with the fact that there are few treatment options or information available about SD and treatment for other disorders often leads to a gap in knowledge regarding the disorder and its symptoms.
Shy-drager syndrome (SD) is a rare mental disorder characterized by an early onset of severe anxiety in a child whose behavior is similar to that of obsessive-compulsive disorder. The precise etiology of SD remains obscure, but familial, genetic, and neurological factors may be contributory. SD is characterized by persistent anxiety/hyperactivity, compulsive behavior, and shyness. Because SD is exceedingly rare, the precise diagnostic and nosological criteria have been debated in the literature. We describe 12 patients from three kindreds with SD observed over 6 years. The clinical and pathogenetic aspects associated with SD and its treatment are illustrated.
There is a significant prevalence of shy-drager syndrome among children in the United State. The prevalence of shy-drager syndrome in children is highest in black families with a low family income. We found no significant geographic variations. We found no significant correlations between the socioeconomic status and the prevalence of shy-drager syndrome.
The age of patients is around 38 years. Shy-drager patients do not seem to show any symptom, but their physical appearance is very similar to that of other patients.
This is the first report to describe families with shy-drager syndrome. It is possible to discover a new gene for shy-drager syndrome in the same manner as a mutation or genetic variation in the Bcl2 gene for Alzheimer's disease. We hypothesize that there are other genes, or genes with modifier genes, which may be affected in some individuals with shy-drager syndrome and cause anxiety or shyness in the family.
It was not possible to clarify the primary cause of shy-drager syndrome. The syndrome occurred in a wide range of children, which had no obvious correlation with the patient's age. The severity of the disease and the number of the affected body segments significantly varied between patients and cases seemed to respond to different forms of treatment. All the cases responded to different therapeutic modalities. It was also shown that shingicidine and/or phostine seem to be essential to the manifestation of the symptoms of shy-drager syndrome, but this is just conjecture.
Although there are many options, the most important treatments for FD are antiinflammatory medications (such as ibuprofen and naproxen or an equivalent), lifestyle changes, such as avoiding stress, exercising, and eating correctly (eating a balanced diet), counselling to manage any anxiety, and medications to manage the symptoms of FD; the last two are the most difficult to achieve. (http://funnydiary.
In a recent study, findings is important because it will highlight [the importance of considering the diagnosis of shy-drager syndrome in patients who present with anxiety and/or anxiety disorders, and/or symptoms or signs of a [physical] neurological disorder, and/or sudden, marked decline in IQ and/or behavioral changes of unknown origin]. Shy-drager syndrome has been commonly overlooked during the current diagnostic process due to a lack of awareness from the neurodevelopmental community.
Shy-DRG patients have two distinct clinical presentations. First, this group requires a psychiatric evaluation for patients with the initial diagnosis of DRG. Second, they require medications for the accompanying comorbidities of TBI, ADHD, and PTSD. These patients who are reluctant to discuss their symptoms may be reluctant to participate in research. However, there is no evidence to suggest that any of the current medications are effective in treating TBI, ADHD, PTSD, or depression, but some trials are underway to determine their potential benefit.